Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

ConditionsSpinal Cord Injury Safety Clinical Trials Efficacy Induced Pluripotent Stem Cells Human Motor Neuron Progenitor Transplantation

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-65

SponsorXellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

About this trial

This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury

Eligibility criteria

Qualifiers

None

Disqualifiers

Neurological Inability

Trial design

Treatments tested in this trial

Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells

Treatment groups

12 Participants

are divided into 1 treatment group

Sponsors and collaborators

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.

Lead sponsor

Third Affiliated Hospital, Sun Yat-Sen University

Collaborator

Source ClinicalTrials.gov